Research programme: anti-Pseudomonas aeruginosa monoclonal antibody - Millenium Biologix
Latest Information Update: 02 Jun 2010
At a glance
- Originator Millenium Biologix Corporation
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pseudomonal infections
Most Recent Events
- 06 Dec 2004 Millenium Biologix has merged with Cytovax Biotechnologies to form Millenium Biologix Corporation
- 16 Jun 2003 This compound is still in active development
- 05 Nov 2001 Preclinical development for Pseudomonal infections in Canada (Unknown route)